Lymphoma with thrombotic thrombocytopenic purpura as the first symptom：report of two cases and literature review

doi:10.12114/j.issn.1007-9572.2020.00.233

Abstract

Abstract: Diffuse large B-cell lymphoma（DLBCL）is the most common type of lymphoma，with various forms of onset.Thrombotic thrombocytopenic purpura（TTP）is a rare and life-threatening thrombotic microangiopathy.DLBCL patients with TTP as the first symptom are rare.We introduced two cases of DLBCL with TTP as the first symptom，summarized the clinical characteristics that easily cause missed diagnosis and misdiagnosis，some highly heterogeneous clinical manifestations，and the treatment and outcome.Moreover，we also discussed the epidemiological characteristics，diagnostic and therapeutic perspectives of TTP based on the review of relevant literature，and concluded that the key to remission is to recognize TTP as early as possible and control DLBCL in time.

Key words: Lymphoma；Purpura, thrombotic thrombocytopenic；Case reports；Signs and symptoms

摘要： 弥漫大B细胞淋巴瘤（DLBCL）是淋巴瘤中最常见的类型，起病形式多样。血栓性血小板减少性紫癜（TTP）是一种少见的、严重危及生命的血栓性微血管病，以TTP为首发症状就诊的DLBCL患者罕见。本文介绍了2例以TTP为首发症状就诊的DLBCL患者，总结了容易漏诊误诊的临床特点、某些异质性较大的临床表现以及治疗、转归，并结合相关文献探讨了TTP的流行病学特点及诊断、治疗思路，指出对于此类患者尽早识别TTP并及时控制原发病是病情缓解的关键。

关键词: 淋巴瘤, 紫癜, 血栓性血小板减少性, 病例报告, 体征和症状

ZHAO Tongde,XU Yamei. Lymphoma with thrombotic thrombocytopenic purpura as the first symptom：report of two cases and literature review[J]. Chinese General Practice, 2020, 23(21): 2727-2730. DOI: 10.12114/j.issn.1007-9572.2020.00.233.
赵同德,许亚梅. 以血栓性血小板减少性紫癜为首发症状的淋巴瘤二例报道并文献复习[J]. 中国全科医学, 2020, 23(21): 2727-2730. DOI: 10.12114/j.issn.1007-9572.2020.00.233.

References

［1］SCULLY M，HUNT B J，BENJAMIN S，et al．Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies［J］．Br J Haematol，2012，158（3）：323-335．DOI：10.1111/j.1365- 2141.2012.09167.x. ［2］张之南，沈悌.血液病诊断及疗效标准［M］．3版.北京：科学出版社，2007：176. ［3］中华医学会血液学分会血栓与止血学组.血栓性血小板减少性紫癜诊断与治疗中国专家共识（2012年版）［J］．中华血液学杂志，2012，33（11）：983-984．DOI：10.3760/cma.j.issn.0253-2727.2012.11.025. ［4］AROMIN M，CHAUHAN A，DAS S S，et al．Bruising，tingling，and numbness in a pale adolescent［J］．Clin Pediatr（Phila），2012，51（7）：697-698．DOI：10.1177/0009922812439246. ［5］MCCORMICK J K，NADEL E S，BROWN D F.Rash and neurological symptoms［J］．J Emerg Med，2007，32（3）：299-303．DOI：10.1016/j.jemermed.2006.12.036. ［6］AIEMPANAKIT K，APINANTRIYO B.Thrombotic thrombocytopenic purpura and hemophagocytic lymphohistiocytosis in an elderly man：a case report［J］．Medicine（Baltimore），2018，97（44）：e13025．DOI：10.1097/MD.0000000000013025. ［7］LARROCHE C.Hemophagocytic lymphohistiocytosis in adults：diagnosis and treatment［J］．Joint Bone Spine，2012，79（4）：356-361．DOI：10.1016/j.jbspin.2011.10.015. ［8］LECHNER K，OBERMEIER H L.Cancer-related microangiopathic hemolytic anemia：clinical and laboratory features in 168 reported cases［J］．Medicine（Baltimore），2012，91（4）：195-205．DOI：10.1097/MD.0b013e3182603598. ［9］ALONSO J V，FONSECA J，LOPERA E L，et al．A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic Purpura［J］．Hematol Rep，2011，3（2）：e14．DOI：10.4081/hr.2011.e14. ［10］VEYRADIER A，OBERT B，HOULLIER A，et al．Specific von willebrand factor-cleaving protease in thrombotic microangiopathies：a study of 111 cases［J］．Blood，2001，98（6）：1765-1772．DOI：10.1182/blood.v98.6.1765. ［11］SILL H，H?FLER G，KAUFMANN P，et al．Angiotropic large cell lymphoma presenting as thrombotic microangiopathy（thrombotic thrombocytopenic purpura）［J］．Cancer，1995，75（5）：1167-1170．DOI：10.1002/1097-0142（19950301）75:5< ；1167::aid-cncr2820750517>；3.0.co；2-1. ［12］BYERS J T，KURTZ J L，MENDOZA A S，et al．An unusual presentation of primary pulmonary extranodal marginal zone lymphoma of mucosal associated lymphoid tissue：an autopsy case report［J］．Exp Mol Pathol，2018，104（2）：155-157． DOI：10.1016/j.yexmp.2018.02.003. ［13］KAWAHARA M，KANNO M，MATSUMOTO M，et al．Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor［J］．Neurology，2004，63（9）：1731-1733．DOI：10.1212/01.wnl.0000143065.55002.67. ［14］KAWANO N，YOKOTA-IKEDA N，YOSHIDA S，et al．Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011［J］．Intern Med，2013，52（17）：1883-1891．DOI：10.2169/internalmedicine.52.8253. ［15］TOMLINSON R，YAXLEY J.Thrombotic thrombocytopenic purpura associated with Hodgkin lymphoma and non-Hodgkin lymphoma［J］．Pathology，2018，50（7）：776-777．DOI：10.1016/j.pathol.2018.05.011. ［16］MARIOTTE E，AZOULAY E，GALICIER L，et al．Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency（thrombotic thrombocytopenic purpura）：a cross-sectional analysis of the French national registry for thrombotic microangiopathy［J］．Lancet Haematol，2016，3（5）：e237-245．DOI：10.1016/S2352-3026（16）30018-7. ［17］GEORGE J N.Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia［J］．Oncology（Williston Park，N Y），2011，25（10）：908-914. ［18］SADLER J E，MUIA J，DOLATSHAHI L，et al．Efficacy of adjuvant low dose rituximab and plasma exchange for acquired TTP with severe ADAMTS13 deficiency——results of the ART study［J］．Blood，2018，132（Supplement 1）：374．DOI： 10.1182/blood-2018-99-113677. ［19］FOLEY S R，ROCK G，BARTH D，et al．A phaseⅡ study evaluating the efficacy of rituximab in the management of patients with relapsed or refractory TTP［J］．Blood，2014，124（21）：4191．DOI：10.1182/blood.v124.21.4191.4191. ［20］STUBBS M J，LOW R，MCGUCKIN S，et al．Single centre UK comparison of biosimilar rituximab（truxima）with the originator（MabThera）in patients with immune mediated thrombotic thrombocytopenic purpura［J］．Blood，2018，132 （Supplement 1）：3750．DOI：10.1182/blood-2018-99-114765. ［21］VON AUER C，HESS G，SCHARRER I.Prevention of complete TTP relapses by immediate initiation of rituximab treatment［J］．Blood，2007，110（11）：3203．DOI：10.1182/blood.v110.11.3203.3203.